Latest news with #ParkSeong-soo
Korea Herald
3 days ago
- Health
- Korea Herald
Daewoong's weekly weight-loss patch hits record absorption in human trial
Daewoong Pharmaceutical and Daewoong Therapeutics said Wednesday their proprietary semaglutide microneedle patch achieved over 80 percent bioavailability compared to injectables, in a pilot pharmacokinetic study on humans. The study, the first human trial of its kind, applied Daewoong Therapeutics' proprietary drug delivery platform, Clopam, to a semaglutide microneedle patch. With 70 healthy adults, the trial compared the blood concentration of semaglutide delivered via the patch to that of a subcutaneous injection, adjusting for dosage differences. While existing microneedle patches with the same ingredient have shown about 30 percent bioavailability, Daewoong's patch demonstrated more than 80 percent -- the highest achievability among similar products -- and around 160 times higher absorption than oral semaglutide tablets. The results also indicated that the patch can maintain stable blood concentration for a week, enabling a weekly, high-dose formulation. According to Grand View Research, the global weight loss medication market is valued at $15.9 billion and is projected to reach $60.5 billion by 2030. Industry experts say that drug delivery technologies offering higher bioavailability and improved patient convenience will be a key factor in shaping the market. Microneedle patch technology, which addresses the limitations of both painful injections and low-efficiency oral drugs, is seen as a potential game changer. Additionally, it also has the advantage of higher cost efficiency, and stability, compared to other methods which require cold temperatures for storage. 'This study proves our ability to deliver a high dose of semaglutide via a single weekly patch — a breakthrough beyond current obesity treatment patches,' said Kang Bok-ki, CEO of Daewoong Therapeutics. 'It's a major step toward global licensing and commercialization.' Daewoong Pharmaceutical CEO Park Seong-soo added, 'Overcoming the high-dose delivery barrier marks a significant milestone. We will expand microneedle applications to other biologics and lead the global platform market.'
Korea Herald
11-06-2025
- Business
- Korea Herald
Daewoong partners with Sweden's Salipro to boost drug discovery
Daewoong Pharmaceutical on Wednesday announced a strategic research partnership with Swedish biotech company Salipro Biotech to jointly develop next-generation therapeutics targeting membrane proteins. Under the agreement, Salipro will provide Daewoong access to its proprietary Salipro Platform, a technology that stabilizes membrane proteins in a near-native environment, making them more accessible for drug discovery. Membrane proteins are involved in essential cellular functions and account for over 60 percent of known drug targets, yet their structural instability in lab conditions has long been a barrier to research. The partnership is Salipro's first with a Korean company and follows previous collaborations with major pharmaceutical firms including Boehringer Ingelheim, Sanofi and Sumitomo. Daewoong views the alliance as a key step in its open innovation strategy, aiming to bolster its global competitiveness and lay the groundwork for potential overseas licensing deals. 'Our partnership with Daewoong marks Salipro's first collaboration with a Korean company, making it especially meaningful,' Jens Frauenfeld, CEO of Salipro Biotech, stated. 'The Salipro platform enables research on previously inaccessible target proteins and is expected to unlock new possibilities in global innovative drug development.' Park Seong-soo, CEO of Daewoong Pharmaceutical, added, 'We expect that the Salipro platform will enhance our access to challenging membrane protein targets and accelerate our drug discovery efforts. Through an open collaboration strategy, we will continue to develop globally competitive new drugs.'
Korea Herald
18-04-2025
- Health
- Korea Herald
Daewoong expands type-2 diabetes treatment Envlo to Latin America, Russian markets
Daewoong Pharmaceutical said Friday that it has submitted regulatory applications for its type 2 diabetes medication Envlo (enavogliflozin) in seven countries, including six in Latin America — Costa Rica, Honduras, the Dominican Republic, Panama, El Salvador and Guatemala — as well as Russia and the other members of the Commonwealth of Independent States. Envlo is Korea's first domestically developed SGLT-2 (sodium-glucose co-transporter 2) inhibitor, a class of drugs that lowers blood sugar by promoting the excretion of glucose and sodium through urine. In addition to glycemic control, the drug has shown benefits for blood pressure, kidney function, cardiovascular health and weight management. Clinical trials have demonstrated that Envlo outperforms global competitor dapagliflozin in key indicators, including glycated hemoglobin (HbA1c), fasting blood glucose, urinary glucose-to-creatinine ratio (UGCR) and insulin resistance (HOMA-IR). According to pharmaceutical market research firm IQVIA, the diabetes treatment market in Latin America and the region encompassing Russia and the Commonwealth of Independent States reached a combined 7 trillion won ($4.9 billion) in 2023. The SGLT-2 inhibitor segment, which includes Envlo, saw especially rapid growth — doubling in Latin America and rising 142 percent in Russia and the other CIS members. In response to this demand, Daewoong is accelerating its global rollout. Envlo is now registered or under regulatory review in 19 countries. 'Our goal is not just market expansion but delivering innovative diabetes care globally,' said Daewoong CEO Park Seong-soo. 'We are committed to strengthening Envlo's presence and achieving our vision of entering 30 countries by 2030.'
